1. Home
  2. AVAV vs INCY Comparison

AVAV vs INCY Comparison

Compare AVAV & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVAV
  • INCY
  • Stock Information
  • Founded
  • AVAV 1971
  • INCY 1991
  • Country
  • AVAV United States
  • INCY United States
  • Employees
  • AVAV N/A
  • INCY N/A
  • Industry
  • AVAV Aerospace
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • AVAV Industrials
  • INCY Health Care
  • Exchange
  • AVAV Nasdaq
  • INCY Nasdaq
  • Market Cap
  • AVAV 18.9B
  • INCY 17.0B
  • IPO Year
  • AVAV 2007
  • INCY 1993
  • Fundamental
  • Price
  • AVAV $331.71
  • INCY $105.22
  • Analyst Decision
  • AVAV Strong Buy
  • INCY Buy
  • Analyst Count
  • AVAV 13
  • INCY 19
  • Target Price
  • AVAV $349.23
  • INCY $89.19
  • AVG Volume (30 Days)
  • AVAV 944.3K
  • INCY 2.8M
  • Earning Date
  • AVAV 12-03-2025
  • INCY 10-28-2025
  • Dividend Yield
  • AVAV N/A
  • INCY N/A
  • EPS Growth
  • AVAV N/A
  • INCY 3878.02
  • EPS
  • AVAV N/A
  • INCY 5.90
  • Revenue
  • AVAV $1,085,820,000.00
  • INCY $4,813,105,000.00
  • Revenue This Year
  • AVAV $148.47
  • INCY $19.33
  • Revenue Next Year
  • AVAV $17.12
  • INCY $10.47
  • P/E Ratio
  • AVAV N/A
  • INCY $17.95
  • Revenue Growth
  • AVAV 44.03
  • INCY 18.09
  • 52 Week Low
  • AVAV $102.25
  • INCY $53.56
  • 52 Week High
  • AVAV $417.86
  • INCY $106.47
  • Technical
  • Relative Strength Index (RSI)
  • AVAV 40.80
  • INCY 79.03
  • Support Level
  • AVAV $359.08
  • INCY $91.16
  • Resistance Level
  • AVAV $378.25
  • INCY $106.47
  • Average True Range (ATR)
  • AVAV 18.26
  • INCY 4.10
  • MACD
  • AVAV -8.77
  • INCY 1.59
  • Stochastic Oscillator
  • AVAV 26.80
  • INCY 94.41

About AVAV AeroVironment Inc.

AeroVironment Inc supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky. The company is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploy autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. Company operates in three segments: UxS, LMS, MW.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: